← Leaderboards
Carole D Mitnick
Harvard Medical School
$5,268,466
Attributed
$9,930,219
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,930,219 · 4
By mechanism
U01$8,493,245 · 1
R01$830,261 · 1
K01$345,959 · 1
R34$260,754 · 1
Top collaborators
- Geraint Davies3 shared
- Megan B Murray2 shared
Most similar at Harvard Medical School
Same institution · by research overlap
- Alan Brown$4,082,203
- Eric Jacobson$585,847
- Mary-Jo Delvecchio Good$458,823
- Theo C Manschreck$991,724
- Eugene Thomas Richardson$751,237
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisTuberculosis TreatmentPeruSputumBaseFailure (Biologic Function)National Institute Of Allergy And Infectious DiseaseAreaPathogenAntitubercular AgentsChronicAffectTuberculosis DrugsDrug ResistanceDetectionProbabilityParticipantPlasmaCommunicable DiseasesPharmaceutical PreparationsPulmonary TuberculosisWeightPersonsEnrollment
Grant awards (9)
Host- and pathogen-specific risk factors for post-tuberculosis lung disease among people successfully treated for TB in Lima, Peru: Beat-PTLD$425,383
R01 · FY2025 · HL · contact PI
Host- and pathogen-specific risk factors for post-tuberculosis lung disease among people successfully treated for TB in Lima, Peru: Beat-PTLD$404,878
R01 · FY2025 · HL · contact PI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB$2,289,159
U01 · FY2013 · AI · contact PI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB$3,094,141
U01 · FY2012 · AI · contact PI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB$3,109,945
U01 · FY2011 · AI · contact PI
Clinical Outcomes Research in MDR-TB$118,040
K01 · FY2008 · AI · contact PI
Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TB$260,754
R34 · FY2007 · AI · contact PI
Clinical Outcomes Research in MDR-TB$115,292
K01 · FY2007 · AI · contact PI
Clinical Outcomes Research in MDR-TB$112,627
K01 · FY2006 · AI · contact PI